lonafarnib has been researched along with imatinib mesylate in 11 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | lonafarnib (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daley, GQ; Hoover, RR; Mahon, FX; Melo, JV | 1 |
| Brodsky, AL | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Druker, BJ | 1 |
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
| Tauchi, T | 1 |
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Kurisu, K; Okamura, T | 1 |
| Borthakur, G; Cortes, J; Daley, G; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Sugrue, M; Talpaz, M | 1 |
| Azam, M; Cortes, J; Daley, GQ; Nardi, V; Raz, T | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
2 review(s) available for lonafarnib and imatinib mesylate
| Article | Year |
|---|---|
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides | 2004 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
2 trial(s) available for lonafarnib and imatinib mesylate
| Article | Year |
|---|---|
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Piperidines; Pyridines; Pyrimidines | 2006 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
7 other study(ies) available for lonafarnib and imatinib mesylate
| Article | Year |
|---|---|
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines | 2002 |
Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.
Topics: Alkyl and Aryl Transferases; Apoptosis; Benzamides; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Piperidines; Pyridines; Pyrimidines; Research Design; Tumor Cells, Cultured | 2003 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Overcoming resistance to imatinib by combining targeted agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Pyridines; Pyrimidines | 2003 |
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis; Mutagenesis, Site-Directed; Mutation; Pilot Projects; Piperazines; Piperidines; Protein Conformation; Protein Prenylation; Pyridines; Pyrimidines; Tumor Cells, Cultured | 2007 |